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ABSTRACT
Familial hypoparathyroidism is an unusual and genetically het-
erogeneous group of disorders that may be isolated or may be asso-
ciated with congenital or acquired abnormalities in other organs or
glands. We have evaluated a family with a novel syndrome of auto-
somal dominant hypoparathyroidism, short stature, and premature
osteoarthritis.
A 74-yr-old female (generation I) presented with hypoparathyroid-
ism, a movement disorder secondary to ectopic calcification of the
cerebellum and basal ganglia, and a history of knee and hip replace-
ments for osteoarthritis. Two members of generation II and one mem-
ber of generation III were also documented with hypoparathyroidism,
short stature, and premature osteoarthritis evident as early as 11 yr.
Because of the known association between autosomal dominant
hypoparathyroidism and activating mutations of the calcium-sensing
receptor (CaR) gene, further studies were performed. Sequencing of
PCR-amplified genomic DNA revealed a leucine to valine substitution
at position 616 in the first transmembrane domain of the CaR, which
cosegregated with the disorder. However, this amino acid sequence
change did not affect the total accumulation of inositol phosphates as
a function of extracellular calcium concentrations in transfected
HEK-293 cells.
In conclusion, a sequence alteration in the coding region of the CaR
gene was identified, but is not conclusively involved in the etiology of
this novel syndrome. The cosegregation of hypoparathyroidism, short
stature, and osteoarthritis in this kindred does suggest a genetic
abnormality involving a common molecular mechanism in parathy-
roid, bone, and cartilage. (J Clin Endocrinol Metab 84: 3036–3040,
1999)
FAMILIAL hypoparathyroidism is an unusual and genet-ically heterogeneous group of disorders of various in-
heritance patterns that may be associated with other abnor-
malities such as autoimmune polyglandular disease (1) and
congenital syndromes such as DiGeorge, Kenney-Caffey, or
Barakat (2). Hypoparathyroidism may also develop as an
isolated entity and most often occurs sporadically, but may
also occur in a familial pattern. In different families, isolated
hypoparathyroidism shows different modes of inheritance
[autosomal dominant (3), autosomal recessive (4), or
X-linked recessive (5)], suggesting that different genetic de-
fects can produce the same phenotype.
Isolated familial hypoparathyroidism has been described
as a result of a mutation of the signal peptide-encoding
region of the preproparathyroid hormone gene on chromo-
some 11p (6). It may also be caused by an activating mutation
of the calcium receptor (CaR) gene located on chromosome
3q (7–13). This receptor belongs to the G protein-coupled
receptor superfamily. CaR transcripts and protein have been
localized to tissues involved in calcium homeostasis includ-
ing parathyroid, C cells of the thyroid, kidney, bone cells (14),
and cartilage (15). Activation of the CaR leads to decreased
secretion of PTH and inhibition of renal calcium reab-
sorption.
We describe a family with a novel syndrome of autosomal
dominant hypoparathyroidism associated with short stature
and premature osteoarthritis and have investigated the pos-
sibility of a mutation in the CaR gene as the cause of this
syndrome.
Subjects and Methods
Case report (Fig. 1 and Table 1)
Family members in three generations were studied after informed
consent was obtained. The study was approved by the NICHHD insti-
tutional review board. The index case (patient I-1) presented at age 74
yr with uncontrolled movement of the left leg. Her past medical history
was significant for multiple lumbar compression fractures at age 68 yr
and hypocalcemia. At age 70 yr the patient underwent bilateral knee and
right hip replacements for degenerative arthritis. The physical exami-
nation was significant for short stature (16) and frequent, involuntary
choreiform movements of the left leg. Additional laboratory studies
revealed a serum albumin concentration of 4.0 g/dL, magnesium of 1.7
mg/dL, and 25-hydroxyvitamin D of 33 ng/mL (normal, 10–55). A
computed tomography scan of the head revealed calcification of the
cerebellum and basal ganglia bilaterally. Over the following 6 months
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she was treated with calcium and vitamin D, and there was dramatic
improvement in her movement disorder.
The patient’s oldest daughter (II-1) presented at age 45 yr with hy-
pocalcemia and a long history of pain in her knees and feet. Her physical
examination was significant only for short stature. The serum magne-
sium concentration was 1.7 mg/dL, and albumin was 3.9 g/dL, and she
was treated with calcium and vitamin D supplementation. At age 49 yr,
knee pain increased, and radiographs revealed moderate degenerative
arthritis.
Patient II-4 first complained of diffuse aches and pains, particularly
of the knees, beginning at age 9 yr. At age 31 yr laboratory studies
revealed hypocalcemia, a serum magnesium concentration of 1.5 mg/
dL, and 25-hydroxyvitamin D of 21 ng/mL. At age 35 yr she underwent
the first of several right knee arthroscopic procedures. The physical
examination revealed short stature and limitation of right knee flexion.
At age 37 yr a right unicondylar knee replacement was performed, and
the articular cartilage was found to be roughened and eroded, consistent
with degenerative arthritis.
Members of generation III were screened. At age 24 yr subject III-1
was found to have short stature and hypocalcemia, and calcium sup-
plementation was suggested. Subject III-2 had been evaluated for short
stature at age 8 yr and was found to have normal GH levels. At age 13
yr he complained of knee pain, and the serum calcium concentration was
8.6 mg/dL (normal, 8.4–10.2). Subject III-3 complained of left knee pain
at age 11 yr, and hypocalcemia was documented. The physical exami-
nation revealed short stature, pectus carinatum, a normal knee exami-
nation, and a negative Chvostek’s sign. Arthroscopy of the left knee was
performed, which revealed lateral patellar subluxation and early vas-
cular ingrowth over the hyaline cartilage surface.
DNA amplification and sequence analysis
Genomic DNA was isolated from white blood cells and exons 1–6 of
the CaR were PCR amplified with previously reported primers (17).
Screening for mutations was performed by heteroduplex analysis using
mutation detection enhancement gels (18). PCR products that showed
heteroduplex bands from members III-2 and III-3 were sequenced using
a fluorescence-based DNA-sequencing system (19).
Restriction analysis
PCR-amplified genomic DNA was digested with restriction enzyme
MaeIII, subjected to electrophoresis through a 6% polyacrylamide gel,
and stained with ethidium bromide.
Site-directed mutagenesis, cell culture, transfection, and
preparation of cell membranes
The human CaR complementary DNA (cDNA) inserted into the mu-
tagenesis vector pAlter I (Promega Corp., Madison, WI) was obtained
from NPS Pharmaceuticals, Inc. (Salt Lake City, UT). The detected nu-
cleotide change (C to G) at nucleotide 1846 of exon 6 or other nucleotide
changes were introduced into this construct by site-directed mutagen-
esis using the Altered Sites II system (Promega Corp.). The mutated
cDNA were then isolated with restriction enzymes XbaI and HindIII,
inserted into the expression vector pcDNAI/Amp (Invitrogen, San
Diego, CA), and confirmed by DNA sequencing.
Cell culture and transfection
HEK-293 cells were cultured in DMEM. The cells were plated in
24-well plates (105 cells/well) and transiently transfected with con-
structs encoding the wild-type and the receptors with nucleotide
changes, using 5 mL Lipofectamine (Life Technologies, Inc., Gaithers-
burg, MD) and 0.5 mg DNA.
Assessment of cell surface receptor expression by enzyme-
linked immunosorbent assay (ELISA)
Transfected cells were suspended in 1% BSA-DMEM for 30 min at 4
C and then incubated with monoclonal antibody 7F8 (20 mg/mL) for 1 h
at 4 C. This antibody was made by immunization with the purified
extracellular domain of the human CaR (Goldsmith, P. K., manuscript
in preparation). After washing, cells were further incubated with per-
oxidase-conjugated goat antimouse secondary antibody (Kirkegaarde &
Perry Laboratories, Inc., Gaithersburg, MD; 1:1000 dilution). After wash-
ing, peroxidase substrate was added. Absorbance was measured at 405
nm. Four independent transfections were performed for ELISA.
Measurement of phosphoinositides (IPs)
Forty-eight hours after transfection, HEK-293 cells were labeled with
3 mCi/mL myo-[3H]inositol (New England Biolabs, Inc., Beverly, MA)
in DMEM for 16–24 h. Cells were then incubated in PI buffer (99 mmol/L
NaCl, 5 mmol/L KCl, 5.6 mmol/L glucose, 0.4 mmol/L Mg Cl2, and 0.5
mmol/L CaCl2) containing 20 mmol/L LiCl for 1 h. Cells were stimu-
lated with the indicated concentrations of Ca21 (in PI buffer) for 30 min
at 37 C. The reactions were terminated with acid-methanol (167 mL HCl
in 120 mL methanol). Total inositol phosphates were extracted, sepa-
rated on Dowex AG1-X8 columns as previously described (Berridge,
1983), and counted by liquid scintillation. Nine independent transfec-
tions were performed at each Ca21 concentration for IP measurement.
Statistical analysis
Results were expressed as the mean 6 sem. Significance was assessed
using an unpaired t test. P , 0.05 was considered statistically significant.
Results
DNA sequence analysis
To screen for sequence alterations in the CaR, individual
exons from genomic DNA were PCR amplified and subject
to heteroduplex analysis. Possibly affected subject III-2 and
definitely affected subject III-3 showed heteroduplex bands
in exon 6 (data not shown). Direct sequencing of PCR-
amplified genomic DNA from possibly affected subject III-2
and definitely affected subject III-3 revealed a heterozygous
C to G basepair substitution at position 1846 in exon 6. This
change produces a leucine to valine substitution at position
616 in the first transmembrane domain of the receptor
(L616V).
Genomic DNA from affected subjects I-1, II-1, II-4, and
III-3 and from possibly affected subjects III-1 and III-2 were
screened for this possible sequence alteration by restriction
FIG. 1. Pedigree of family with hypoparathyroidism, short stature,
and premature osteoarthritis. Darkened symbols represent affected
members. Subject III-1 was found to have hypoparathyroidism and
short stature at age 24 yr and is possibly affected. Subject III-2 was
found to have a low normal serum calcium concentration, short stat-
ure, and knee pain and is possibly affected.
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analysis. All of these members were found to have additional
fragments representing a possible mutant allele cut by MaeIII
(Fig. 2).
Assessment of receptor expression (Table 2)
Cell surface expression of the L616V construct and wild-
type CaRs on the plasma membranes of transfected and
control HEK-293 cells was assessed by ELISA. The mean cell
surface expression was lower for L616V than for the wild-
type receptor.
Functional analysis (Fig. 3 and Table 2)
After transient transfection with wild-type or possible mu-
tant constructs, HEK-293 cells were exposed to graded Ca21
concentrations, and IP accumulation was measured. There
was no significant difference in the maximal or minimal
response to Ca21. Although there may have been a slight
leftward shift in the concentration-response curve for the
L616V receptor, the decrease in EC50 compared to that for the
wild-type receptor did not quite reach statistical significance
(P 5 0.054).
Discussion
We have described a family with mild hypoparathyroid-
ism associated with short stature and premature osteoar-
thritis, inherited in an autosomal dominant pattern. To our
knowledge, this is the first report of this association. We
considered a mutation in the CaR gene in members of this
family in view of recent reports demonstrating gain of func-
tion mutations in the extracellular domain of the CaR in
families with autosomal dominant hypoparathyroidism (9).
Given the report of CaR expression in human bone cells (14)
and in animal articular and growth plate cartilage (15), we
also hypothesized that an abnormality in the CaR in bone or
cartilage might also contribute to the familial short stature
and premature osteoarthritis in this family.
In our study we found a heterozygous C to G basepair
substitution at position 1846 in exon 6 that cosegregated with
the disorder. This basepair change produced a change in the
amino acid sequence of leucine to valine at amino acid po-
sition 616. This amino acid sequence change did not affect
total accumulation of inositol phosphates as a function of
extracellular calcium concentrations in transfected HEK-293
cells.
In the same experiment, we measured the function of the
activating mutation F612S, identified in a family with auto-
somal dominant hypoparathyroidism. The results have been
reported previously (12) and serve as a positive control com-
pared to the wild-type results in Table 2. This mutation
produced a leftward shift in the concentration-response
curve, with a decrease in the EC50 to 2.3 6 0.06 mmol/L (P ,
0.001) and an increase in the maximum IP accumulation to
42 6 3 3 103 cpm (P , 0.02) compared to wild-type values.
However, the cell surface receptor expression in our in
vitro system was decreased for L616V compared to wild-type
receptors. In the same experiment, the cell surface expression
of mutation F612S was also lower than that in wild-type
receptors (1.3 6 0.6 optical density units), but did not reach
FIG. 2. MaeIII restriction enzyme digest of PCR-amplified exon 6
DNA from family members. MaeIII recognizes a site created by the
C1846G basepair substitution in exon 6. The unaffected family mem-
bers (I-2, lane 1; II-2, lane 8; II-3, lane 4) show a single band that
represents the two wild-type alleles. The affected family members
with hypoparathyroidism, short stature, and premature osteoarthri-
tis (I-1, lane 2; II-1, lane 7; II-4, lane 3; III-3, lane 6) all show the
wild-type band and two additional fragments that represent the mu-
tant allele cut by MaeIII. Possibly affected family members (III-1, lane
9; III-2, lane 5) also demonstrate the wild-type band and the two
additional fragments.
TABLE 1. Clinical and biochemical features of members of a kindred with autosomal dominant hypoparathyroidism, short stature, and
premature osteoarthritis
Subject
no. Age (yr)
Serum
calcium
(mg/dL)
Serum
phosphorus
(mg/dL)a
Serum PTH
Urinary
calcium
(mg/24 h)
Ht (%)b Osteoarthritis
I-1 74 7.8c 5.6 21 pg/mLd 133e ,5 1
II-1 45 6.0f 3.8 27 ng/dLg 146,208h ,5 1
II-4 31 7.8i 4.0 21 pg/mLd 54e ,5 1
III-1 24 7.9f 4.0 31 pmol/Lj ,10 2
III-2 13 8.6c 6.4 140 pg/mLk 68 ,5 2
III-3 11 8.1c 5.6 110 pg/mLk 24 5 1
a Normal, 2.5–4.5 mg/dL.
b Percent 18 yr-old height for adults and percent age-matched height for subjects III-2 and III-3 (16).
c Normal, 8.4–10.2 mg/dL.
d Normal, 10–65 pg/mL, intact.
e While taking calcium and ergocalciferol.
f Normal, 8.5–10.5 mg/dL.
g Normal, 0–180 ng/dL, C-terminal.
h While taking calcium, ergocalciferol, and hydrochlorothiazide/triamterine.
i Normal, 9-0–10.6 mg/dL.
j Normal, 18–120 pmol/L, C-terminal.
k Normal, 50–340 pg/mL, midregion.
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statistical significance (P 5 0.06) (12). The signal transduction
activity per receptor may be higher for L616V than for wild-
type receptors. If the cell surface expression of the L616V
receptor in vivo was similar to that of the wild-type receptor,
then this possibly increased activity per receptor might ac-
count for the phenotype. Alternatively, a mutation in the
promoter or in other regulatory genes for the expression of
the CaR cannot be ruled out. It is also possible that this
sequence alteration may affect another signal transduction
pathway or that the causative mutation lies in a nearby gene.
There are several families with autosomal dominant hypo-
parathyroidism in whom CaR mutations have not been doc-
umented despite extensive analysis (8, 9).
A clinical issue to be considered in caring for members of
this family is surveillance for ectopic calcifications, which
have had significant effects on family member I-1 despite the
mild nature of her disease. Basal ganglia calcifications and
subsequent movement disorders have been described in
mild chronic hypoparathyroidism (20). Periodic brain imag-
ing studies might be performed in these patients. Whether
treatment of affected members to raise their serum calcium
concentrations to low normal levels will be of benefit in
preventing or delaying ectopic calcifications remains to be
elucidated. Hypercalciuria, usually a concern in the treat-
ment of hypoparathyroidism, was not demonstrated in this
family. Hypercalciuria has been found in families with doc-
umented mutations of the CaR, probably related to a de-
crease in the tubular reabsorption of calcium (10).
The description of this family extends previous observa-
tions that familial hypoparathyroidism is a heterogeneous
disorder. A sequence alteration in the coding region of the
CaR gene was identified and cosegregates with the pheno-
type, suggesting a causal relationship. However, the expres-
sion data and functional analysis do not conclusively dem-
onstrate that this sequence alteration activates the receptor.
The association of hypoparathyroidism, short stature, and
osteoarthritis in this kindred does suggest a genetic abnor-
mality involving a common molecular mechanism in para-
thyroid, bone, and cartilage.
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